We recently described that the polyphenol oleuropein aglycone, a non-glyceridic constituent of EVOO, was capable to reverse breast cancer acquired autoresistance to the anti-HER2 monoclonal antibody trastuzumab (HerceptinTM) [20]. Here, ERBB2 is linked to breast carcinoma.